Sulfanilamide (paraaminobenzenesulfonamide) is effective in the treatment of infections due to beta hemolytic streptococci. Clinical and experimental observations indicate that this chemotherapeutic agent may be of value in the treatment of infections caused by the less virulent classes of streptococci. The hemolytic streptococci designated as the alpha group include Streptococcus viridans. Bliss, Long and Feinstone1 observed that the growth of forty-two of forty-five strains of alpha hemolytic streptococci was inhibited by a 1: 10,000 concentration of the drug.2 Long and Bliss3 found that sulfanilamide exerted a definite bacteriostatic effect in urine cultures of alpha streptococci. It would be desirable to ascertain the effect of sulfanilamide on the lesions of animals infected with the less virulent groups of streptococci, but such infections are not easily produced. Muether and Kinsella4 stated that they established bacterial endocarditis with persistent bacteremia in dogs, using a culture of nonhemolytic streptococci. After daily oral administrations of
SPINK WW, CRAGO FH. EVALUATION OF SULFANILAMIDE IN THE TREATMENT OF PATIENTS WITH SUBACUTE BACTERIAL ENDOCARDITIS. Arch Intern Med (Chic). 1939;64(2):228–248. doi:10.1001/archinte.1939.00190020014002
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: